厄贝沙坦联合吡格列酮对糖尿病肾病尿VEGF 水平的影响

目的:研究厄贝沙坦联合吡格列酮对糖尿病肾病(DN)患者尿VEGF水平的影响.方法:选择糖尿病肾病患者60例,根据尿微量白蛋白排泄率(UAER)分为微量白蛋白尿组(30例)和临床蛋白尿组(30例),每组均分为三个亚组,分别采用格列吡嗪(A组)、吡格列酮(B组)和厄贝沙坦+吡格列酮(C组)连续治疗3个月,在治疗第8周、第10周和第12周分别比较各亚组间尿VEGF水平.结果:在治疗第8周、第10周和第12周,C组分别与A组和B组的尿VEGF水平比较,差异均具有统计学意义(P＜0.05),C组的临床效果均显著优于A组和B组.结论:DN患者应首选厄贝沙坦+吡格列酮药物治疗,可显著提高临床疗效,延缓病程进展.

The VEGF Levels' Influence of Irbesartan Combined with Pioglitazonein Treatment of Diabetic Nephropathy

Objective: To investigate the effect of VEGF levels Irbesartan combined with Pioglitazone in treatment of diabetic nephropathy.Method: Collect 60 patients with diabetic nephropathy,according to the UAER,they were divided into the microalbumin-uria group(30 cases) and clinical proteinuria(30 cases).Each group were divided into three subgroups,compared with the urinary VEGF levels in the subgroups after eight weeks’ treatment,ten weeks’ treatment and twelve weeks’ treatment.Result: After eight weeks’ treat-ment,ten weeks’ treatment and twelve weeks’ treatment,there was significant statistical difference(P<0.05) in the urinary VEGF levels in three groups,the C group’s clinical effects were better than that in the A group’s and B group’s.Conclusion: It should choose Irbesartan combined with Pioglitazone in treatment of diabetic nephropathy,and it could significantly improve the clinical effect and delay the dis-ease progression.